Physician profile
Jack Rutkowski
NPI 1073602520
$7,848.21
in general payments reported to CMS, 2019-2025
48 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $2,034 · 2021: $1,607 · 2022: $1,429 · 2023: $655 · 2024: $805 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,772.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $919.71 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Allergan, INC. | $697.13 | 2019-2020 | |
| Lilly USA, LLC | $526.26 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $488.98 | 2019-2024 | Breztri, Airsupra |
| Pfizer INC. | $413.86 | 2019-2025 | |
| Amgen INC. | $379.91 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $331.90 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $298.33 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $295.81 | 2022-2024 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $240.57 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $237.44 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $200.13 | 2019-2022 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $179.21 | 2019-2022 | |
| Glaxosmithkline, LLC. | $172.32 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceutical Holding Company Ltd. | $152.63 | 2022 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Rutkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.